SeaStar Medical receives Nasdaq public reprimand for Rule 5635(d) violation; listing unaffected

SeaStar Medical Holding Corp

Nasdaq staff issued public reprimand for failure to obtain shareholder approval for issuance of 625,722 shares below minimum price in amendments to convertible notes and warrants.
Company bought back all remaining additional warrants; no outstanding balance on notes, and shareholders ratified transaction at Nov. 2024 special meeting.
Delisting was deemed not appropriate; listing of common stock remains unaffected.
118,207 shares from warrant exercise and 170,625 from additional warrants were issued at prices below the floor price.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.